Most Read Articles
Yesterday
Nontraditional eating patterns, such as skipped or delayed breakfast, are potentially linked to mood disorders, according to a study.
6 days ago
Among postmenopausal women, short sleep duration and depression contribute to increased fall accidents, as reported in a study.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
15 Jan 2021
Among patients with moderate-to-severe psoriasis, the use of biologics appears to lower the risk of being hospitalized for the novel coronavirus disease (COVID-19), a new study has found.

Product Highlight - MEROMAX IV

17 Dec 2020
  • Meropenem (Meromax IV) remains the most reliable option against multi-drug resistant gram negative pathogens:
    - ESBL E. coli and Klebsiella pneumonia 95% and 89% susceptible to meropenem1.
    - Pseudomonas aeruginosa 86% susceptibility rate1.
  • Meropenem (Meromax IV) associated with higher survival rate among patients with severe infections due to MDR gram negatives:
    - Lower mortality rate in patients with severe pneumonia, UTI, intra-abdominal
    - infections and sepsis vs. comparator agents2.
    - Superior efficacy against ESBL Klebsiella pneumoniae bacteremia3.
    - Combination of carbapenem and colistin is associated with higher survival against KPC-Klebsiella pneumoniae vs. colistin alone4.

References:
1. 2017 DOH Antimicrobial Resistance Surveillance Program.
2. Clinical Infectious Diseases 2017;64(7):972–80.
3. Clinical Infectious Diseases 2017;64(7):972–80.
4. Clinical Microbiology and Infection 24 (2018) 133e144.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Philippines digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Yesterday
Nontraditional eating patterns, such as skipped or delayed breakfast, are potentially linked to mood disorders, according to a study.
6 days ago
Among postmenopausal women, short sleep duration and depression contribute to increased fall accidents, as reported in a study.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
15 Jan 2021
Among patients with moderate-to-severe psoriasis, the use of biologics appears to lower the risk of being hospitalized for the novel coronavirus disease (COVID-19), a new study has found.